-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $22

Benzinga·09/08/2025 14:40:27
Listen to the news
Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $44 to $22.